Table 4.
Adverse and serious adverse events up to 6 months of observation
| Most reported adverse events (AEs) n (%) | N = 99 |
|---|---|
| Constipation | 21 (21.2) |
| Insufficient effect | 6 (6.1) |
| Lack of efficacy | 6 (6.1) |
| Diarrhea | 5 (5.1) |
| Injection site reaction | 2 (2.0) |
| Serious adverse events (SAEs) n (%) | 12 (12.1) |
| Anaphylactic shocka | 1 (1.0) |
| Chest pain and arm pain left side | 1 (1.0) |
| COVID-19 | 1 (1.0) |
| Inpatient headache therapy | 2 (2.0) |
| Kidney stone | 1 (1.0) |
| Medication overuse headache needing withdrawal in hospital setting | 1 (1.0) |
| Meningioma | 1 (1.0) |
| Mycoplasma pneumonia | 1 (1.0) |
| Right motor and sensory syndrome and migraine | 1 (1.0) |
| Transitory ischemic attack | 1 (1.0) |
| Urinary tract infection | 1 (1.0) |
aFour months after erenumab discontinuation, hence no causal relationship assumed
Abbreviations: AE Adverse event, SAE Serious adverse event